Imperial Companies Imperial Blog
News/Events

Press Releases

<< Back to Press Releases

Imperial Joins the Avoca Quality Consortium

Contact Us

May 19, 2017

For more information, contact:
Brandon Bissell
616.784.0100
connect@imperialcrs.com


Imperial Joins the Avoca Quality Consortium

GRAND RAPIDS, Michigan (May 19, 2017) – Imperial Clinical Research Services has joined the Avoca Quality Consortium (AQC), a group of nearly 70 pharma, biotech, and clinical services companies that collaborate to make tangible improvements in the execution of clinical trials.

“We are delighted to join our colleagues in a shared mission of fostering excellence,” said Steve Swanson, president of Imperial. “We bring 60-plus years of experience supporting clinical trials
to the group, and we look forward to many years of working together for this important cause,”
he said.

“We are pleased to welcome Imperial Clinical Research Services to the AQC and are delighted to have them as part of the Consortium. Each new company adds to the depth, diversity and influence of our collaborative, and it is particularly important to have clinical service providers like Imperial engaged, contributing thought leadership and their perspective,” said Patricia Leuchten, president and CEO of The Avoca Group.

AQC is the only consortium that engages sponsors and CROs in improving clinical trial quality, reducing risk, and facilitating communication among industry leaders. It is sponsored by Eli Lilly and Pfizer and led by The Avoca Group, which is based in Princeton, N.J. The Avoca group provides research, training, and consulting services in the areas of clinical outsourcing, business development, and client service. More information is available at www.theavocagroup.com.

About Imperial
Imperial Clinical Research Services, based in Grand Rapids, Michigan, provides patient engagement, creative, and translation services; ancillary clinical study supplies; and site material production, fulfillment, and distribution worldwide.
www.imperialcrs.com - +1 800-777-2591 (U.S.) or +44 020 3887 3437 (U.K.).

Download Press Release

<< Back to Press Releases

<< Back to News/Events